Rasuvo Autoinjector Launched for RA, pJIA, Psoriasis

Rasuvo Autoinjector Launched for RA, pJIA, Psoriasis
Rasuvo Autoinjector Launched for RA, pJIA, Psoriasis

Medac Pharma announced the launch of Rasuvo (methotrexate) injection for patients with rheumatoid arthritis, polyarticular course juvenile idiopathic arthritis (pJIA), and psoriasis, following its approval in July 2014.

Rasuvo is a subcutaneous autoinjector that contains methotrexate, a folate analog metabolic inhibitor. It works by interfering with DNA synthesis, repair, and cellular replication.

The company has also launched CORE Connections, a program that provides information, materials, and assistance to help patients and healthcare providers use Rasuvo.

RELATED: FDA Approves Rasuvo Injection for RA, JIA, Psoriasis

Rasuvo autoinjector is available in the following dosage strengths: 7.5mg/0.15mL, 10mg/0.20mL, 12.5mg/0.25mL, 15mg/0.30mL, 17.5mg/0.35mL, 20mg/0.40mL, 22.5mg/0.45mL, 25mg/0.50mL, 27.5mg/0.55mL, and 30mg/0.60mL in 1- and 4-count packs.

For more information call (855) 336-3322 or visit Rasuvo.com.

Loading links....